Headlines after the bell: T, AMGN, VMW» Read More
NEW YORK— Gilead Sciences said Tuesday that sales of its hepatitis C pill Sovaldi totaled more than $2 billion in its first full quarter on the market, and it said quarterly net income tripled. The company reported $2.27 billion in first-quarter sales of Sovaldi, which was launched in the U.S. during December and was approved in Europe in January.
April 22- Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.
April 22- Gilead Sciences Inc, whose pricing policy ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.
Amgen Inc. rose $1.56 or 1.4 percent, to $117.02. Biogen Idec rose $7.44 or 2.6 percent, to $297.98. Celgene Corp. rose $2.32 or 1.6 percent, to $143.83.
Amgen Inc. rose$. 89 or. 8 percent, to $116.35. Biogen Idec rose $3.44 or 1.2 percent, to $293.98. Celgene Corp. rose $1.03 or. 7 percent, to $142.54.
Cisco Systems Inc. rose. 8 percent to $23.40 with 38,516,700 shares traded. Facebook Inc. rose 3.9 percent to $61.24 with 58,657,400 shares traded. FuelCell Energy Inc. rose 2.9 percent to $2.52 with 17,673,900 shares traded.
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
Amgen Inc. rose$. 91 or. 8 percent, to $116.37. Biogen Idec rose $3.58 or 1.2 percent, to $294.12. Celgene Corp. rose $1.63 or 1.2 percent, to $143.14.
About 150 S&P 500 companies are scheduled to release results this week, in an earnings season that has been mediocre.
April 18- Biogen Idec Inc is pricing its newly approved long-acting hemophilia drug, Alprolix, to cost U.S. patients, and insurers, about the same per year as older, less convenient therapies whose price can reach about $300,000 annually.
Some medical groups now want doctors to consider both the effectiveness and costs of treatment options.
Several behemoths, including Apple, the largest U.S. company by market value, as well as Microsoft, McDonald's and AT&T, are due to report earnings.
*Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks ended a holiday-shortened week with mostly modest gains on Thursday, though the S&P 500 notched its biggest weekly advance since July as Morgan Stanley and General Electric rallied after strong results.
*Google, IBM shares fall a day after posting earnings. NEW YORK, April 17- U.S. stocks advanced slightly in choppy trading on Thursday after three days of gains, as underwhelming results from tech bellwethers Google and IBM were offset by upbeat quarterly numbers, including those from Morgan Stanley and General Electric.
Some of Thursday's midday movers:
April 17- UnitedHealth Group Inc, the largest U.S. health insurer, said on Thursday it has spent more than $100 million to cover a pricey new hepatitis C drug from Gilead Sciences Inc, a higher cost than it expected by "multiples," sending shares in the sector lower.
The $9.4 billion Fidelity Select Biotechnology Fund plunged 11.75 percent during the first 14 days of April. That put the fund near the bottom among nearly 3,800 U.S. mutual funds tracked by Lipper Inc. Only six funds performed worse, but they had less than $100 million in assets each.
UnitedHealth Group's first-quarter net income slid 8 percent as funding cuts to a key product and costs imposed by the health care overhaul dented the health insurer's performance.
Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.
Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.